Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study

Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study

Abstract Objective: To compare a once-daily long-acting β2 agonist (indacaterol 150 µg) with a once-daily long-acting anticholinergic (tiotropium 5 µg) in terms of their effects on exercise endurance (limit of tolerance, Tlim) in patients with moderate COPD. Secondary endpoints were their effects o...

Full description

Bibliographic Details
Main Authors:	Danilo Cortozi Berton, Álvaro Huber dos Santos, Ivo Bohn Jr., Rodrigo Quevedo de Lima, Vanderléia Breda, Paulo José Zimermann Teixeira
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Pneumologia e Tisiologia
Series:	Jornal Brasileiro de Pneumologia
Subjects:	Pulmonary disease, chronic obstructive Exercise Bronchodilator agents
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132016000500367&lng=en&tlng=en

Similar Items

Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study
by: Fujimoto K, et al.
Published: (2017-11-01)

Tiotropium as essential maintenance therapy in COPD
by: M. Decramer
Published: (2006-12-01)

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial
by: Claus F. Vogelmeier, et al.
Published: (2017-07-01)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
by: Wedzicha JA, et al.
Published: (2017-01-01)

The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study – the FAVOR study
by: Kardos P, et al.
Published: (2017-12-01)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
by: Gong S, et al.
Published: (2021-02-01)

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US
by: Rajagopalan K, et al.
Published: (2018-11-01)

A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study
by: Lehmann S, et al.
Published: (2019-01-01)

Effects of combination therapy indacaterol/glycopyrronium versus tiotropium on moderate to severe COPD: evaluation of impulse oscillometry and exacerbation rate
by: Antonio Molino, et al.
Published: (2017-09-01)

Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance
by: D. E. O'Donnell
Published: (2006-12-01)

Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age
by: Ferguson GT, et al.
Published: (2016-10-01)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
by: Ridolo E, et al.
Published: (2019-01-01)

Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD
by: Chan M, et al.
Published: (2018-04-01)

Tiotropium: a new therapeutic option in asthma
by: F. Novelli, et al.
Published: (2013-12-01)

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
by: Anthony D’Urzo, et al.
Published: (2019-03-01)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studies
by: Ichinose M, et al.
Published: (2016-08-01)

Eficacia del indacaterol como broncodilatador en un grupo de pacientes asmáticos
by: Juan Carlos Rodríguez Vázquez, et al.

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
by: Plate T, et al.
Published: (2020-06-01)

Reducing cholinergic constriction: the major reversible mechanism in COPD
by: V. Brusasco
Published: (2006-12-01)

Tiotropium in asthma: back to the future of anticholinergic treatment
by: Matteo Bonini, et al.
Published: (2017-12-01)

INFLOW study: a prospective observational study for assessment of indacaterol and other bronchodilators in symptomatic chronic obstructive pulmonary disease patients from Egypt
by: Waleed M. El-Sorougi, et al.
Published: (2017-01-01)

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
by: Sethi S, et al.
Published: (2019-03-01)

Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline
by: Jeong HJ, et al.
Published: (2016-11-01)

Prevention of exacerbations of COPD with pharmacotherapy
by: M. Miravitlles
Published: (2010-06-01)

The Impact of Bronchodilator Therapy on Systolic Heart Failure with Concomitant Mild to Moderate COPD
by: Mahoto Kato, et al.
Published: (2017-12-01)

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

Investigation of the efficacy of generic and brand-name tiotropium bromide in the management of chronic obstructive pulmonary disease: A randomized comparative trial
by: Yunes Panahi, et al.
Published: (2016-03-01)

Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study
by: Kawachi S, et al.
Published: (2019-05-01)

Clinical experience of using double bronchodilation therapy in patients with COPD
by: I. V. Demko, et al.
Published: (2019-12-01)

Exercise and dyspnoea in COPD
by: P. M. A. Calverley
Published: (2006-12-01)

When is dual bronchodilation indicated in COPD?
by: Thomas M, et al.
Published: (2017-08-01)

Global initiative gold and national recommendations on the management of patients with chronic obstructive pulmonary disease (COPD): the place of double bronchodilation
by: A. A. Vizel, et al.
Published: (2019-12-01)

A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
by: Ferguson GT, et al.
Published: (2021-04-01)

Bronchodilator treatment of stable COPD: long-acting anticholinergics
by: W. Vincken
Published: (2005-09-01)

Comparison of the variability of the annual rates of change in FEV<sub>1</sub> determined from serial measurements of the pre- versus post-bronchodilator FEV<sub>1</sub> over 5 years in mild to moderate COPD: Results of the lung health study
by: Tashkin Donald P, et al.
Published: (2012-08-01)

Lung hyperinflation in COPD: the impact of pharmacotherapy
by: D. E. O'Donnell, et al.
Published: (2006-12-01)

Heart and Lungs in COPD. Close friends in real life - separate in daily medical practice?
by: M. Lusuardi, et al.
Published: (2016-01-01)

Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
by: Pascoe S, et al.
Published: (2016-08-01)

Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts
by: Se Hee Lee, et al.
Published: (2019-03-01)

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
by: Beier J, et al.
Published: (2017-06-01)

Cannot write session to /tmp/vufind_sessions/sess_0hmi7qlnc2if44cji4mrilqvt8